Contact Us

*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Street Address 

Zip Code 



Date you started taking this drug:

Date you stopped taking this drug:

Please describe side effects:

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.


NeutroSpec Side Effects Lawsuits | Side Effects: Cardiopulmonary Failure, Cardiac Arrest, Hypoxia, Dyspnea, Hypotension

NeutroSpec Side Effects May Lead To Cardiac Arrest Lawsuits

NeutroSpec | Lawsuits, Lawyers | Side Effects: Cardiopulmonary Failure, Cardiac Arrest, Hypoxia, Dyspnea, Hypotension

NeutroSpec is a radio-pharmaceutical imaging agent approved in the United States for the diagnosis of equivocal appendicitis has been removed from the market. The manufacturer, Palatin Technologies Inc. and marketing partner, Mallinckrodt, removed NeutroSpec after the FDA said the drug can cause severe, life-threatening reactions in some people. NeutroSpec is injected into a patient's bloodstream to help doctors diagnose ailments.

The companies said that two deaths attributed to cardiopulmonary failure, and additional cases of serious cardiopulmonary events, including cardiac arrest, hypoxia, dyspnea, and hypotension, occurred within 30 minutes of their injection with NeutroSpec. The majority of the reactions occurred in patients with underlying cardiopulmonary disease who received NeutroSpec for unapproved indications. Physicians often prescribe approved medications for off-label use.

NeutroSpec, approved for marketing in July 2004, is a diagnostic imaging agent that is administered intravenously to help diagnose appendicitis in patients five years and older with possible appendicitis who do not show the conventional signs and symptoms. The FDA said the decision to suspend marketing was based on the life-threatening nature of the adverse events, the unpredictability of the reaction, and availability of other means of diagnosing appendicitis that do not carry these risks.

Legal Help For Victims Of NeutroSpec

If you or a loved were administered NeutroSpec and suffered side effects, please fill out the form at the right for a free case evaluation by a qualified drug side effects attorney or Call us anytime at 1-800-YOURLAWYER (1-800-968-7529).


NeutroSpecRSS Feed

Blood cell tracer pulled from market

Dec 20, 2005 | AP
A fairly new drug used to diagnose appendicitis was pulled off the market Monday after the government linked it to two deaths and life-threatening side effects.The Food and Drug Administration ordered that NeutroSpec, an imaging agent, be taken off the market, and it warned health workers to stop using any of the drug still on their shelves.Manufacturer Palatin Technologies said it would suspend sales and recall past shipments.There is no risk to anyone who already received NeutroSpec, the FDA...

Deaths and Several Serious Adverse Events Lead to Recall of NeutroSpec, a Drug Used to Diagnose Appendicitis

Dec 20, 2005 |
Following the FDA’s request, Palatin Technologies Inc., the makers of NeutroSpec, an imaging agent used to diagnose appendicitis, are withdrawing the product from the market.There have been now been two deaths and 20 “serious and life-threatening” complications linked to the use of the agent, according to the FDA. Those complications occurred within minutes of injection of the drug and have included cardiopulmonary failure, central nervous system reactions, and infusion...

Local drugmaker's product, NeutroSpec, is off the shelf

Dec 20, 2005 |
A key product used by doctors in diagnosing cases of appendicitis and the first product to emerge from the labs of Palatin Technologies was pulled from the market yesterday after the U.S. Food and Drug Administration said it should not be administered until it is better understood.That request followed two deaths and a number of severe reactions possibly related to use of the product.NeutroSpec held promise in that it reportedly could dramatically speed up the diagnosis of hard-to-recognize...

FDA Wants NeutroSpec Withdrawn From Market

Dec 20, 2005 | Consumer Affairs
The Food and Drug Administration (FDA) has issued an alert about NeutroSpec, a diagnostic imaging agent injected into a patient's bloodstream to help doctors diagnose ailments, saying it may cause severe, life-threatening reactions in some people.The manufacturer, Palatin Technologies Inc. and marketing partner, Mallinckrodt, have agreed to implement an immediate voluntary market suspension.The adverse event reports submitted to FDA as part of the agency's routine postmarket surveillance of all...

Palatin Recalls NeutroSpec After Deaths

Dec 19, 2005 | AP
Drug developer Palatin Technologies Inc. said Monday that it is recalling its NeutroSpec medical imaging agent and suspending sales of the product until adverse events can be studied further.The company said that the imaging agent, which had been approved by the Food and Drug Administration in July 2004 for imaging appendicitis, was linked to two deaths and several adverse events after being used for unapproved uses. Palatin said the deaths occurred in patients with heart problems.At a meeting...

More NeutroSpec News

Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo